Importantly, targeting the FGF19/FGFR4 axis by administering ponatinib, a third-generation Table 2 inhibitor for chronic myelogenous leukemia treatment, can overcome resistance to sorafenib in HCC by enhancing ROS-related apoptosis (Gao et al., 2017). This evidence concerns the gene FGFR4 and hepatocellular carcinoma.